Skip to main content

Table 1 Clinical characteristics of control donors and hospitalized patients with COVID-19

From: Transcriptional landscape of circulating platelets from patients with COVID-19 reveals key subnetworks and regulators underlying SARS-CoV-2 infection: implications for immunothrombosis

 

Control donors

COVID-19 patients

P-value

(n = 8)

(n = 10)

Age, years

47.25 (± 8.31)

45.80 (± 13.76)

0.797a

Gender, male

4 (50%)

6 (60%)

0.520b

Comorbidities

 

Hypertension

0 (0%)

3 (30%)

 

Diabetes

0 (0%)

2 (20%)

 

Cancer

0 (0%)

1 (10%)

 

Hyperlipidemia

3 (37.5%)

0 (0%)

 

Heart disease

0 (0%)

0 (0%)

 

DVT

0 (0%)

0 (0%)

 

Symptom

 

Fever

0 (0%)

8 (80%)

 

Cough

0 (0%)

8 (80%)

 

Expectoration

0 (0%)

5 (50%)

 

Sore throat

0 (0%)

3 (30%)

 

Fatigue

0 (0%)

1 (10%)

 

Muscle ache

0 (0%)

2 (20%)

 

Chest tightness

0 (0%)

0 (0%)

 

Nausea

0 (0%)

1 (10%)

 

Diarrhea

0 (0%)

0 (0%)

 

Physical signs

 

Respiratory rate

 

20 (18–20)

 

Heart rate

 

85 (75–92)

 

Laboratory findings on admission

CRP, mg/dL

1.41 (± 1.78)

22.51 (± 25.65)

0.029a

Leukocytes, × 109/L

5.39 (± 1.34)

4.85 (± 1.54)

0.440a

Neutrophils, × 109/L

3.10 (± 0.85)

3.00 (± 1.33)

0.846a

Lymphocytes, × 109/L

1.88 (± 0.66)

1.27 (± 0.28)

0.037a

Platelet count, × 109/L

294.25 (± 44.52)

212.40 (± 70.70)

0.009a

MPV, fl

10.06 (± 0.81)

9.78 (± 0.51)

0.407a

PT, S

12.31 (± 0.75)

13.73 (± 0.25)

0.399a

APTT, S

36.40 (± 4.19)

45.47 (± 5.17)

0.001a

Fibrinogen, mg/Dl

2.86 (± 0.54)

4.76 (± 0.87)

 < 0.001a

ALT, U/L

21.25 (± 10.47)

26.70 (± 5.76)

0.215a

Creatinine, μmol/L

60.34 (± 12.74)

66.75 (± 21.00)

0.440a

  1. DVT, deep vein thrombosis; CRP, C reactive protein; MPV, mean platelet volume; PT, prothrombin time; APTT, activated partial thromboplastin time; ALT, alanine aminotransferase
  2. a Two-tailed Student T test
  3. b Chi-square test